

A SYNTHETIC ROUTE TO CARBOCYCLIC AMINONUCLEOSIDES

Susan Daluge and Robert Vince*
 Department of Medicinal Chemistry, College of Pharmacy
 University of Minnesota, Minneapolis, MN 55455

(Received in USA 28 May 1976; received in UK for publication 9 July 1976)

The antitumor activities of 6-dimethylamino-9-(3'-amino-3'-deoxy- β -D-ribofuranosyl)-purine (puromycin aminonucleoside) and 3'-amino-3'-deoxyadenosine have generated considerable interest in the biological properties of aminonucleosides.¹ A second class of nucleoside analogs which possesses biological activity is the carbocyclic nucleosides which contain a cyclopentane ring in place of the tetrahydrofuran ring.^{2,3} For reasons explained previously,⁴ the hybridization of these two types of nucleosides into one molecule should provide a novel class of nucleoside analogs with potential chemotherapeutic properties. We now report a stereoselective synthesis of the "carbocyclic aminonucleoside" analogs of puromycin aminonucleoside, 3'-amino-3'-deoxyadenoside, and 3'-amino-3'-deoxyarabinosyladenine.

The recent description of an unequivocal route to 2-azabicyclo[2.2.1]hept-5-en-3-one (1)⁵ offers a unique starting point for the synthesis of carbocyclic aminonucleosides of known geometric configuration. Acidic hydrolysis of 1 (2 N HCl, 25°) to cis-4-aminocyclopent-2-ene carboxylic acid hydrochloride, followed by esterification of the carboxyl function in refluxing methanol and subsequent acetylation of the amino group in acetic anhydride-pyridine, gave 2 [90% (after sublimation at 0.003 mm); mp 66-67°; m/e 183; ir (KBr) 1725, 1622, 1535 cm⁻¹; pmr (CDCl₃) δ 6.25 (br, NH), 5.82 (br s, CH=CH), 4.97 (m, CH-N), 3.68 (s, OCH₃), 3.64 (m, CH), 2.7-1.5 (m, CH₂) overlapping 1.91 (s, CH₃CO)]. Reduction of the methyl ester of 2 with CaBH₄ (THF, 25°, 18hr) gave, after acetylation, acetate 3 [89%; bp 132-134° (0.2mm); mp 45-47°; m/e 197; ir (neat) 1735, 1638, 1530 cm⁻¹; pmr (CCl₄) δ 7.83 (br d, J=7.5 Hz, NHC=O), 5.83 (br s, CH=CH), 4.93 (m, CH-N), 4.04 (d, J=6.5 Hz, O-CH₂-CH), 3.25-2.18 (m, CH and $\frac{1}{2}$ CH₂), 2.07 and 1.95 (both s, CH₃C=O, CH₃C-N), 1.63-1.07 (m, $\frac{1}{2}$ CH₂)]. Epoxidation of 3 with m-chloroperbenzoic acid (CCl₄, reflux, 2 hr) was stereoselective due to the syn-directing allylic amide group,⁶ giving only the cis-epoxide 4 [89%; mp 68-72°; m/e 213; ir (KBr) 1735, 1635, 1540, 830, 865; pmr (CDCl₃) δ 6.98 (br d, J=7.5 Hz, NHC=O), 4.42 (m, CH-N), 4.03 (d, J=7.0 Hz, O-CH₂-CH), 3.6-3.3 (m, CH-CH), 2.09 and 2.03 (both s, CH₃C=O and CH₃C-N) overlapping 2.7-0.5 (m, CH, CH₂). Removal of the acetate group (NH₃ in MeOH) gave 5. Reaction of 5 with sodium azide (aqueous methoxyethanol, buffered by NH₄Cl, 75°, 18hr) gave, after acetylation, azide 6 as the major product [83%; mp 103-104°; ir (KBr) 3255, 3090, 2110, 1745, 1645, 1555 cm⁻¹; pmr (CDCl₃) δ 6.38 (br d, J=8 Hz, NHC=O), 5.00 (m, CH-O), 4.8-4.2

-2-

(m, CH-NHCO), 4.12 (d, $J=5.5$ Hz, O-CH₂-CH), 4.60 (m, CH-N₃), 2.14, 2.12, 2.00 (all s, 3 CH₃C=O) overlapping 2.8-1.3 (m, CH, CH₂). A minor product, azide 11, was detected by pmr of mother liquors. Hydrogenation of azide 6 (Pt, 50 psi H₂, Ac₂O solvent) gave diacetamide 7 [70%; mp 167-168°; m/e 314; ir (KBr) 1737, 1653, 1553 cm⁻¹; pmr (CDCl₃) δ 7.18 (br d, $J=8$ Hz, NHC=O), 6.46 (br d, $J=8$ Hz, NHC=O), 5.3-3.9 (m, CH-O, 2 CH-N, O-CH₂), 2.11, 2.08, 2.01 (all s, 4 CH₃C=O) overlapping 2.8-1.7 (m, CH, CH₂). Hydrogenation of mother liquors containing a mixture of 6 and 11 gave diacetamide 12 [separated from 7 by chromatography on silica gel, 2% MeOH-CHCl₃; 10% from 5; mp 163.5-164.5°; m/e 314; ir (KBr) 1745, 1730 sh, 1650, 1635 sh, 1550; pmr (CDCl₃) δ 7.5-7.1 (m, 2 NHC=O), 5.4-5.3 (m, CH-O), 4.6-3.7 (m, 2 CH-N, O-CH₂), 2.07, 2.03, 1.98 (all s, 4 CH₃C=O) overlapped by 3.0-1.2 (m, CH, CH₂)].

The structure assignment of 7 and 12 was confirmed by acyl migration studies. When 7 was subjected to mild acidic hydrolysis (2 N HCl, 70°, 1 hr), a monoacetamide 8 was formed since acyl migration to a *cis*-hydroxyl facilitates hydrolysis of one acetamido group. The *cis*-geometry of the amino and secondary hydroxyl groups of 8 was further confirmed by conversion to the N-carbobenzyloxy derivative 9 [44%; mp 152.5-153.5°; m/e 322; ir (KBr) 1688, 1640, 1537 cm⁻¹; pmr (DMSO-*d*₆) δ 7.98 (br d, $J=7.5$ Hz, NHC=O), 7.37 (br s, C₆H₅), 6.63 (br d, $J=7.5$ Hz, NHC=O), 5.07 (s, O-CH₂-Ph) overlapped by 5.0-4.7 (m, OH), 4.3-3.0 (m, O-CH, 2 N-CH, O-CH₂-CH, OH), 1.68 (s, CH₃C=O) overlapped by 2.3-1.0 (m, CH₂, CH)]. Treatment of 9 with base (NaOMe in DMF, 100°, 1.5 hr), followed by acetylation, gave cyclic carbamate 10 [82%; mp 168-174° efferves.; m/e 298; ir (KBr) 1770, 1735, 1697, 1635, 1540 cm⁻¹; pmr (DMSO-*d*₆) δ 8.10 (br d, $J=8.0$ Hz, NHC=O), 5.0-3.7 (m, CH-O, 2 CH-N, CH₂-O), 2.40, 2.02, 1.88 (all s, 3 CH₃C=O) overlapped by 2.4-1.0 (m, CH, CH₂)].

When 12 was subjected to the same acidic hydrolysis, diacetamide 13 was formed, characterized as the monomethoxytrityl derivative 14 [51% from 12; mp 158-160° efferves.; m/e 502; ir (KBr) 1650 br, 1550 br cm⁻¹; pmr (CDCl₃) δ 7.6-6.5 (m, 2 C₆H₅, MeOC₆H₄, NHC=O), 6.40 (br d, $J=6.0$ Hz, NHC=O), 4.43 (br s, OH), 4.2-3.5 (m, CH-O, 2 CH-N) overlapping 3.78 (s, OCH₃), 3.30 (br d, $J=5.8$ Hz, O-CH₂-CH), 1.95, 1.87 (both s, 2 CH₃C=O) overlapped by 2.7-1.2 (m, CH₂, CH)]. The purine moiety was formed by condensation of 8 with 5-amino-4,6-dichloropyrimidine (*n*-BuOH, Et₃N, reflux 18 hr) and ring closure of the resulting pyrimidine 15 (76%; mp 254-256° dec) with diethoxymethyl acetate. The resulting 6-chloropurine compound (not isolated) was reacted with NH₃, giving the carbocyclic 3'-acetamido-3'-deoxyarabinosyl-adenine analog, 16 [71%; mp 218-222° dec; m/e 306, 136, 135; uv max (0.1 N HCl) 260 nm (ϵ 1.48 x 10⁴), 258 (1.45 x 10⁴); ir (KBr) 1670, 1650, 1607, 1545 cm⁻¹; pmr (DMSO-*d*₆) δ 8.08 (s, purine H-2 and H-8) overlapping 8.1-7.9 (br, NHC=O), 7.07 (br s, NH₂), 5.5-3.1 (m, 2-OH, CH-O, 2 CH-N, CH₂-O, H₂O), 1.89 (s, CH₃C=O) overlapped by 2.5-1.3 (m, CH, CH₂)]. Hydrolysis of 16 [Ba(OH)₂, reflux 6 hr] gave the carbocyclic 3'-amino-3'-deoxyarabinosyladenine, 22 [66%; mp 199-201°; ir (KBr) 1680, 1650, 1570 cm⁻¹].

The 6-amino group of 16 was blocked by reaction with *N,N*-dimethylformamide dimethyl acetal (DMF, 25°), giving 17 (94%; mp 227-231° dec.). The 5'-hydroxyl group was then blocked

-3-

by reaction with chloro(*p*-methoxyphenyl)diphenyl methane, followed by removal of the 6-N-(dimethylamino)methylene group with NH_3 , giving the 5'-O-mono-*p*-methoxytrityl compound, 18 (75%, mp: collapses to glass at 150-154°, melts at ca. 240° dec). Treatment of 18 with methane sulfonyl chloride in pyridine (1.5 eq, 25°, 3 days), followed by hydrolysis (NaOAc, 65°, 18hr) gave the epimerized product, 19 (69%, mp: turns to glass at 160°, efferves. at ca. 200°). Detritylation of 19 (97% HCOOH, 25°, 4hr) gave the 3'-acetamido carbocyclic adenosine analog, 20 [90%; m/e 306; mp 153-154°; ir (KBr) 1670, 1635, 1595, 1560 cm^{-1} ; uv max (0.1 N HCl) 258 nm (ϵ 1.43 x 10⁴), (0.1 N Na OH) 260 (1.47 x 10⁴); pmr (DMSO-d₆) δ 8.13, 8.07 (both s, purine H-2 and H-8), 7.67 (br d, NHC=O), 7.10 (br s, NH_2), 6.5-3.0 (CH-O, 2CH-N, 2 OH, CH_2 -O), 1.90 (s, $\text{CH}_3\text{C=O}$) overlapped by 2.5-1.1 (m, CH, CH_2)]. Hydrolysis of 20 [Ba(OH)₂, reflux, 2hr] gave the ribonucleoside analog, 21, (+)-9-[β -(3 α -amino-2 α -hydroxy-4 β -(hydroxymethyl) cyclopentyl)]adenine [95% as acetic acid salt hemihydrate; solid foam; m/e 264; ir (KBr) 3500-3000 br, 1650, 1600, 1575 cm^{-1} ; uv max (0.1 N HCl) 258 nm (ϵ 1.44 x 10⁴), (0.1 N NaOH) 260 (1.48 x 10⁴).

In an analogous series of reactions, the 6-dimethylamino analog 23 was prepared (63% from 15; mp 250-252° dec; m/e 334, 163, 164). The 5'-monomethoxytrityl derivative 24 (92%; mp 195-196°; m/e 334, 163, 164) was treated with methane sulfonyl chloride, then NaOAc, and the resulting 2'-epimer, 25 (72%, solid foam), detritylated to 26 [76%; mp 169-170°; m/e 334, 163, 164; ir (KBr) 1650, 1595, 1550; uv max (0.1 N HCl) 268 nm (ϵ 1.82 x 10⁴), (0.1 N NaOH) 275.5 (1.85 x 10⁴). Hydrolysis of 26 gave the carbocyclic analog of puromycin aminonucleoside, 27, which was converted to carbocyclic puromycin, 28, via standard methods.^{4,7}

Acknowledgements:

This investigation was supported by Grant Number CA 13592 and Career Development Award CA 2525A from the National Cancer Institute, DHEW.

References and Notes:

1. R.J. Suhadolnik, "Nucleoside Antibiotics," Wiley, New York, NY, 1970, pp. 76-91.
2. Y.F. Shealy and J.D. Clayton, *J. Amer. Chem. Soc.*, 91, 3075 (1969).
3. L.L. Bennett, Jr., P.W. Allan, and D.L. Hill, *Mol. Pharmacol.*, 4, 208 (1968).
4. S. Daluge and R. Vince, *J. Med. Chem.*, 15, 171 (1972).
5. J.C. Jagt and A.M. van Leusen, *J. Org. Chem.*, 39, 564 (1974).
6. G. Berti, "Stereochemistry of Epoxide Synthesis," in "Topics in Stereochemistry," vol. 7, N.L. Allinger and E.L. Eliel, Ed., Wiley, New York, NY, 1973, p. 93.
7. R. Vince and S. Daluge, *J. Med. Chem.*, 17, 578 (1974).

